Our current projects focus on the medicinal cannabis sector, offering comprehensive licensing, education, R&D, cultivation, extraction, and transportation services. Additionally, we are dedicated to the development of rare cannabinoids, specifically targeting disorders with high unmet medical needs.
We also offer delivery of bespoke solutions designed and executed to exacting standards to fulfil your specific needs.
If you'd like to know more about our investment opportunities or how we can help your business, please contact us today.
Regulatory approval can be the foundation that business is built on, and provides a recognised benchmark of integrity to your customers, partners and employees. We have worked with and for a variety of Regulatory authorities in a diverse range of sectors, taking businesses through their approvals process and onto a path of sustainable growth.
All businesses go through cycles that can see things plateau, and Regulatory changes can also raise challenges that hinder growth. Both these events can also foster new opportunities. With decades of experience of strategic collaboration in a diverse selection of industries, we can provide a fresh perspective to impact positive results.
There are well over 500 different active molecules present in the cannabis plant. These molecules have never been clinically tested in combination. We hope to develop blends of rare cannabinoids to transform rare diseases with high levels of unmet need.
The "entourage effect" refers to the various compounds in cannabis, usually cannabinoids, terpenes and flavonoids, working together synergistically, enhancing each other's effects and providing a more comprehensive therapeutic benefit than any single compound alone. Our project aims to harness the entourage effect by creating a blend of molecules that work synergistically together to alleviate the symptoms associated with our indication spaces. Currently cannabinoid-based medications focus on cannabinoids in isolation or in pairs and do not benefit from the entourage effect.
The new vertically integrated medicinal cannabis company aims to leverage the Isle of Man’s renewable energy resources to become a centre of excellence for medicinal cannabis-based products addressing a range of diverse indications. With ambitions to be the leading cultivator on the Isle of Man, the company is committed to delivering quality and consistency at scale. It focuses on developing pharmaceutical-grade medicinal cannabis products compliant with the European Union Good Manufacturing Practices (EU GMP) framework.
We are working closely with the Isle of Man Government, which passed legislation in 2021 enabling the production and export of cannabis products, to establish a highly competitive value proposition in the medicinal cannabis market. Leveraging the Isle of Man as a strategic gateway into Europe, we aim to seize opportunities to penetrate global markets. Our approach focuses on using novel cannabinoid blends to enhance the Entourage Cascade Effect for our target indications, significantly improving patients' quality of life. Specifically, we target rare cannabinoid formulations to benefit individuals living with chronic, poorly managed. Backed by extensive experience in cannabinoid development and a deep understanding of regulatory pathways for controlled substances, our team is well-positioned to drive therapeutic advancements in this evolving sector.